SCHEMBL372183

SCHEMBL372183

O=Cc1cc2ccccc2nc1I

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.53
GAA P10253 4/20 0.53
HPGD P15428 4/20 0.46
MAPT P10636 3/20 0.46
GLA P06280 1/20 0.46
ACHE P22303 1/20 0.46
LMNA P02545 5/20 0.46
NPSR1 Q6W5P4 3/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
RXFP1 Q9HBX9 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 1/20 0.41
TDP1 Q9NUW8 2/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL8833034 0.96 ALDH1A1 (0.50) ALDH1A1GAAHPGDMAPTGLA
SCHEMBL7891555 0.78 ALDH1A1 (0.54) ALDH1A1GAAHPGDMAPTGLA
SCHEMBL715554 0.78 ALDH1A1 (0.58) ALDH1A1GAAHPGDMAPTGLA
SCHEMBL30081463 0.78 ALDH1A1 (0.58) ALDH1A1GAAHPGDMAPTGLA
SCHEMBL6340621 0.77 ALDH1A1 (0.53) ALDH1A1GAAHPGDMAPTGLA
SCHEMBL688007 0.77 TDP1 (0.53) ALDH1A1GAAHPGDMAPTGLA
SCHEMBL372264 0.77 ALDH1A1 (0.62) ALDH1A1GAAHPGDMAPTGLA
SCHEMBL807146 0.77 TLR8 (0.55) ALDH1A1GAAHPGDMAPTGLA
SCHEMBL11109074 0.77 ALDH1A1 (0.53) ALDH1A1GAAHPGDMAPTGLA
SCHEMBL29953988 0.77 ALDH1A1 (0.53) ALDH1A1GAAHPGDMAPTGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 EP disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 US disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 WO disclosed
EP-2261212-B1 Preparation of quinoline-substituted carbamate derivatives ABBVIE INC (US) 2016-08-31 EP disclosed
EP-2409964-B1 Process for the preparation of carbonate derivatives ABBOTT LAB (US) 2016-01-27 EP disclosed
EP-1192139-B1 Preparation of quinoline-substituted carbonate and carbamate derivatives ABBOTT LAB (US) 2012-04-18 EP disclosed
EP-2409964-A2 Preparation of substituted carbonate and carbamate derivatives Abbott Laboratories (US) 2012-01-25 EP disclosed
EP-2261212-A2 Preparation of quinoline-substituted carbonate and carbamate derivatives Abbott Laboratories (US) 2010-12-15 EP disclosed
CN-100355734-C Preparation of quinoline-substituted carbonate and carbamate derivatives ABBOTT LAB (US) 2007-12-19 CN disclosed
US-5258516-A Optically pure D,E ring intermediates useful for the synthesis of camptothecin and camptothecin analogs NC STATE UNIVERSITY (US) 1993-11-02 US disclosed
EP-0565621-A1 METHOD OF MAKING CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS NORTH CAROLINA STATE UNIVERSITY (US) 1993-10-20 EP disclosed
US-5254690-A Alkoxymethylpyridine d-ring intermediates useful for the synthesis of camptpthecin and camptothecin analogs NORTH CAROLINA STATE UNIVERSITY (US) 1993-10-19 US disclosed
US-5247089-A Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs NORTH CAROLINA STATE UNIVERSITY (US) 1993-09-21 US disclosed
US-5243050-A Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs NORTH CAROLINA STATE UNIVERSITY (US) 1993-09-07 US disclosed
US-5212317-A Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs NORTH CAROLINA STATE UNIVERSITY (US) 1993-05-18 US disclosed
US-5200524-A Camptothecin intermediates and method of making same NORTH CAROLINA STATE UNIVERSITY (US) 1993-04-06 US disclosed
US-5191082-A Camptothecin intermediate and method of making camptothecin intermediates NORTH CAROLINA STATE UNIVERSITY (US) 1993-03-02 US disclosed
US-5162532-A INTERMEDIATES AND METHOD OF MAKING CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS NORTH CAROLINA STATE UNIVERSITY (US) 1992-11-10 US disclosed
WO-1992011263-A1 METHOD OF MAKING CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS NORTH CAROLINA STATE UNIVERSITY (US) 1992-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 ALDH1A1 3122/4885GAA 817/4885HPGD 2117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.